ESCROW DETAILS Sample Clauses

ESCROW DETAILS. Escrow details: [***] ​ ​ [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ​ [***] ​ [***] ​ [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ​ ​ ​ CAMBRIDGE, England, & BOSTON – [TBD], 2020 – Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle’s use of Pepscan’s CLIPS peptide technology. ​ The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay €3 million upfront, will pay €1 million on the first anniversary of the date of settlement, and will make potential additional payments to Pepscan based on achievement of specified clinical, regulatory and commercial milestones. ​ Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more info...
Sample 1
AutoNDA by SimpleDocs
ESCROW DETAILS. On the Closing Date, SAMC LLC, JGB Capital LP, JGB Capital Offshore Ltd. shall wire transfer an aggregate of $3,125,000 in immediately available funds (comprised of separate wire transfers in the amounts of $1,562,500, $781,250 and $781,250, respectively) to the account set forth below, representing the funds to be placed into escrow pursuant to this Agreement:
Sample 1

Related to ESCROW DETAILS

  • Payment Details payments due to the School by Parents under this agreement or from time to time due to the School by Parents must be made to the School paid by BACS to Widford Lodge School Ltd, Account number: 00000000, Sort Code: 60-05-13. The Parents should use the Child’s name as reference when making any payment.

  • Account Details (a) Account for delivery of Shares to Dealer: To be furnished (b) Account for delivery of Shares to Counterparty: To be furnished (c) Account for payments to Counterparty: To be advised under separate cover or telephone confirmed prior to each Settlement Date (d) Account for payments to Dealer: To be advised under separate cover or telephone confirmed prior to each Settlement Date

  • Contact details 9.1. Any notice, demand, offer or other written instrument required or permitted to be given pursuant to this Standard Transmission Agreement and to the Access Code for Transmission shall be sent to the contact persons mentioned in the contact details sheet as published on the Fluxys Belgium website. The duly filled contact details sheet will be added to attachment 1 of this Agreement. 9.2. Each Party may change these contact detail to which notice shall be sent, or specify one additional address to which copies of notices shall be sent, in accordance with the provisions of this Standard Transmission Agreement.

  • Notice Details Party A: Swiss Re Financial Products Corporation Address: 55 East 52/nd/ Street 39/th/ Floor Xxx Xxxx XX 00000 XXX Xxxxxxxxx Xx.: +0 000 000 0000 Xxxxxxxxx: Head of Operations Xxxxx X: Permanent Financing (No. 6) PLC Address: Blackwell House Guildhall Yard Xxxxxx XX0X 0XX Xxxxxxxxx Xxxxxx: 000 0000 0000 Xxxxxxxxx: The Secretary With a copy to: (i) the Security Trustee:

  • Account Closure At any time, for any reason, we may take any of these actions subject to applicable law:

  • Wire Instructions Please see attached.

  • PROCUREMENT LOBBYING To the extent this agreement is a "procurement contract" as defined by State Finance Law Sections 139-j and 139-k, by signing this agreement the contractor certifies and affirms that all disclosures made in accordance with State Finance Law Sections 139-j and 139-k are complete, true and accurate. In the event such certification is found to be intentionally false or intentionally incomplete, the State may terminate the agreement by providing written notification to the Contractor in accordance with the terms of the agreement.

  • Escrow Arrangement The Company and the Purchaser shall enter into an escrow arrangement with Xxxxxxx Xxxxxx & Green, P.C. (the "Escrow Agent") in the Form of EXHIBIT B hereto respecting payment against delivery of the Shares.

  • Invoice Detail All charges for services rendered or for reimbursement of expenses authorized by Department pursuant to the Grant Work Plan shall be submitted to Department in sufficient detail for a proper pre-audit and post-audit to be performed. The Grantee shall only invoice Department for deliverables that are completed in accordance with the Grant Work Plan.

  • Legal Details All legal details and proceedings in connection with the transactions contemplated by this Agreement and the other Loan Documents shall be in form and substance satisfactory to the Agent and counsel for the Agent, and the Agent shall have received all such other counterpart originals or certified or other copies of such documents and proceedings in connection with such transactions, in form and substance satisfactory to the Agent and said counsel, as the Agent or said counsel may reasonably request.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!